Remove 2029 Remove Insurance Coverage and Processing Remove Packaging
article thumbnail

AbbVie buys $2.1bn Capstan, adding new in vivo CAR-T to pipeline

Pharmaceutical Technology

According to William Blair, forecast revenue rate from 2024 to 2029 growth rate for AbbVie trails only Eli Lilly and Sanofi, representing an “attractive opportunity” for long-term investors. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

article thumbnail

CHMP rejects Elevidys in latest setback for Sarepta

Pharmaceutical Technology

EU’s Pharma Package falls short of Europe’s goal of global competitiveness Why can’t the US figure out weight loss drug prices? According to GlobalData, the CGT market was estimated to be $5.88bn in 2023 and is projected to reach $80bn by 2029. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.